Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the industry as a whole is fielding a lot of questions. The maker of ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

On an adjusted basis, Lilly earned $3.34 per share for the quarter, compared with analysts’ estimates of $3.02 per share ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY -3.19%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Drugmaker Eli Lilly (LLY ... FDA-approved oral GLP-1 drug, Rybelsus, but its impact on weight loss has been moderate. Orforglipron, being an oral drug, will benefit Lilly in a few ways.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Could the long-running obesity drugs leadership anchored by the Denmark-headquartered Novo Nordisk (NVO) be finally coming to an end? While arch rival Eli ... actual impact. Yet, Lilly has ...